These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 2127468)
1. [Treatment of mesothelioma with interferon gamma and interleukin 2]. Boutin C; Viallat JR; Astoul P Rev Pneumol Clin; 1990; 46(5):211-5. PubMed ID: 2127468 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659 [TBL] [Abstract][Full Text] [Related]
3. [Malignant mesothelioma: study of prognostic factors in a series of 188 cases]. Viallat JR; Boutin C; Rey F; Astoul P; Farisse P Arch Anat Cytol Pathol; 1993; 41(5-6):205-11. PubMed ID: 8135581 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Lucchi M; Chella A; Melfi F; Dini P; Ambrogi M; Fino L; Fontanini G; Mussi A Eur J Cardiothorac Surg; 2007 Mar; 31(3):529-33; discussion 533-4. PubMed ID: 17188885 [TBL] [Abstract][Full Text] [Related]
5. [Treatment of malignant mesothelioma using intrapleural gamma interferon]. Boutin C Bull Acad Natl Med; 1990 Mar; 174(3):421-6; discussion 427. PubMed ID: 2117478 [TBL] [Abstract][Full Text] [Related]
6. [Malignant mesothelioma: prognostic factors in a series of 125 patients studied from 1973 to 1987]. Boutin C; Rey F; Gouvernet J Bull Acad Natl Med; 1992 Jan; 176(1):105-14; discussion 115-7. PubMed ID: 1606507 [TBL] [Abstract][Full Text] [Related]
7. [The kinetics of IL-2 after pleural administration in the treatment of neoplastic pleurisy]. Astoul P; Bertault-Peres P; Durand A; Boutin C Rev Mal Respir; 1994; 11(1):29-35. PubMed ID: 8128091 [TBL] [Abstract][Full Text] [Related]
8. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial. Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752 [TBL] [Abstract][Full Text] [Related]
9. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Astoul P; Picat-Joossen D; Viallat JR; Boutin C Cancer; 1998 Nov; 83(10):2099-104. PubMed ID: 9827714 [TBL] [Abstract][Full Text] [Related]
10. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Goey SH; Eggermont AM; Punt CJ; Slingerland R; Gratama JW; Oosterom R; Oskam R; Bolhuis RL; Stoter G Br J Cancer; 1995 Nov; 72(5):1283-8. PubMed ID: 7577483 [TBL] [Abstract][Full Text] [Related]
11. Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study. Monnet I; Breau JL; Moro D; Lena H; Eymard JC; Ménard O; Vuillez JP; Chokri M; Romet-Lemonne JL; Lopez M Chest; 2002 Jun; 121(6):1921-7. PubMed ID: 12065358 [TBL] [Abstract][Full Text] [Related]
13. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. Castagneto B; Zai S; Mutti L; Lazzaro A; Ridolfi R; Piccolini E; Ardizzoni A; Fumagalli L; Valsuani G; Botta M Lung Cancer; 2001; 31(2-3):303-10. PubMed ID: 11165411 [TBL] [Abstract][Full Text] [Related]
14. Diffuse malignant mesothelioma of the pleura--intrapleural treatment with doxorubicin. Matzel W; Büchel O Arch Geschwulstforsch; 1987; 57(3):209-18. PubMed ID: 3619593 [TBL] [Abstract][Full Text] [Related]
15. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537 [TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694 [TBL] [Abstract][Full Text] [Related]
17. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. Kasseyet S; Astoul P; Boutin C Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568 [TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma. Matsuzaki Y; Tomita M; Shimizu T; Hara M; Ayabe T; Onitsuka T Ann Thorac Cardiovasc Surg; 2008 Jun; 14(3):161-5. PubMed ID: 18577894 [TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Halme M; Knuuttila A; Vehmas T; Tammilehto L; Mäntylä M; Salo J; Mattson K Br J Cancer; 1999 Aug; 80(11):1781-5. PubMed ID: 10468296 [TBL] [Abstract][Full Text] [Related]
20. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer. Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]